Evidence map›Paper›PMID 38821101›Full record

ReviewThe Lancet. Oncology2024

Addressing challenges in low-income and middle-income countries through novel radiotherapy research opportunities.

May Abdel-Wahab, C Norman Coleman, Jesper Grau Eriksen, Peter Lee, Ryan Kraus, Ekaterina Harsdorf, Becky Lee, Adam Dicker, Ezra Hahn, Jai Prakash Agarwal and 19 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Lancet. Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Article
  3. Observational
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

May Abdel-WahabDivision of Human Health, International Atomic Energy Agency, Vienna, Austria. Electronic address: m.abdel-wahab@iaea.org.
C Norman ColemanRadiation Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Jesper Grau EriksenDepartment of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus, Denmark.
Peter LeeDivision of Human Health, International Atomic Energy Agency, Vienna, Austria.
Ryan KrausDepartment of Radiation Oncology, Barrow Neurological Institute, Phoenix, AZ, USA.
Ekaterina HarsdorfDivision of Human Health, International Atomic Energy Agency, Vienna, Austria.
Becky LeeDepartment of Radiation Medicine, Loma Linda University, Loma Linda, CA, USA; Department of Radiation Oncology, Summa Health, Akron, OH, USA.
Adam DickerDepartment of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA, USA.
Ezra HahnDepartment of Radiation Oncology, Radiation Medicine Program, Princess Margaret Cancer Centre, University of Toronto, ON, Canada.
Jai Prakash AgarwalDepartment of Radiation Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.
Pataje G S PrasannaRadiation Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Michael MacManusDepartment of Radiation Oncology, Peter MacCallum Cancer Centre and the Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.
Paul KeallImage X Institute, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
Nina A MayrCollege of Human Medicine, Michigan State University, East Lansing, MI, USA.
Barbara Alicja Jereczek-FossaDepartment of Oncology and Hemato-oncology, University of Milan, Milan, Italy; Division of Radiotherapy, European Institute of Oncology, IRCCS, Milan, Italy.
Francesco GiammarileDivision of Human Health, International Atomic Energy Agency, Vienna, Austria.
In Ah KimDepartment of Radiation Oncology, Seoul National University Bundang Hospital, Seoul, South Korea; Seoul National University, College of Medicine, Seoul, South Korea.
Ajay AggarwalDepartment of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London, UK; Guy's and St Thomas' NHS Foundation Trust, London, UK.
Grant LewisonInstitute of Cancer Policy, King's College London, London, UK.
Jiade J LuShanghai Proton and Heavy Ion Centre, Fudan University School of Medicine, Shanghai, China.
Douglas Guedes de CastroDepartment of Radiation Oncology, Hcor and Hospital Alemão Oswaldo Cruz, São Paulo, Brazil.
Feng-Ming Spring KongDepartment of Clinical Oncology, HKU-Shenzhen Hospital and Queen Mary Hospital, Li Ka Shing Faculty of Medicine, Hong Kong Special Administrative Region, China.
Haidy AfifiDivision of Human Health, International Atomic Energy Agency, Vienna, Austria.
Hamish SharpInstitute of Cancer Policy, King's College London, London, UK.
Verna VanderpuyeNational Center for Radiotherapy, Oncology and Nuclear Medicine, Korlebu Teaching Hospital, Accra, Ghana.
Tajudeen OlasindeAhmedu Bello University Teaching Hospital, Zaria, Nigeria.
Fadi AtrashAugusta Victoria Hospital, Jerusalem, Israel.
Luc GoethalsDivision of Human Health, International Atomic Energy Agency, Vienna, Austria.
Benjamin W CornShaare Zedek Medical Center, Jerusalem, Israel.

Funding

Intramural NIH HHS Z99 CA999999
6 · The paper itself

Abstract

Although radiotherapy continues to evolve as a mainstay of the oncological armamentarium, research and innovation in radiotherapy in low-income and middle-income countries (LMICs) faces challenges. This third Series paper examines the current state of LMIC radiotherapy research and provides new data from a 2022 survey undertaken by the International Atomic Energy Agency and new data on funding. In the context of LMIC-related challenges and impediments, we explore several developments and advances-such as deep phenotyping, real-time targeting, and artificial intelligence-to flag specific opportunities with applicability and relevance for resource-constrained settings. Given the pressing nature of cancer in LMICs, we also highlight some best practices and address the broader need to develop the research workforce of the future. This Series paper thereby serves as a resource for radiation professionals.

Indexed as

Developing CountriesNeoplasmsRadiation OncologyBiomedical ResearchHumansPovertyRadiotherapy

Identifiers

PMID38821101
PMCPMC11382686

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.